Products
At TREOS we use our proprietary platform technonolgy to predict human’s immune response to a wide range of cancers and disease pathogens. We use this knowledge to create highly effective immunotherapies against different cancers and preventive vaccines against emergent viral diseases. These treatments can be created for an individual or for a general human population.
Peptide Cancer Immunotherapies
TREOS’ system has enabled us to develop two families of cost-effective, industrially scalable, rapidly delivered, off-the-shelf personalized products without the need for tumor biopsy.
PolyPEPI™ Off-the-shelf Peptide Cancer Immunotherapies
Off-the-shelf products contain 6-12 shared tumor-specific antigen derived peptides optimized for a population. They are personalized with a candidate companion diagnostic test (CDx). Clinical trials conducted with our lead product, PolyPEPI1018, consistently confirmed exceptionally broad T cell responses against at least 3 tumor antigens in high proportion of patients, conform to model predictions.
TREOS proprietary Off-the-shelf PolyPEPI™ peptide cancer immunotherapies and CDx are in development to the following indications:
Personalized Peptide Cancer Immunotherapies
PEPI Panel – A unique approach for off-the-shelf personalized cancer immunotherapy generation.
Our Peptide Library (PEPI Panel) currently contains 3,286 proprietary, immunogenic peptide fragments from 184 tumor antigens associated with 19 cancer indications that induce immune responses in the largest subpopulation of subjects, based on HLA genotype (both class I and II) of 16,000 subjects. PEPI Panel approach guides selection of 12 individual peptides tailored to the tumor type and HLA genotype of patients from a warehouse of off-the-shelf peptides permitting the administration of personalized immunotherapy with unprecedently broad immunogenicity (Csiszovszki et al SITC 2019).
Treos’ differentiated and scalable approach provides substantial competitive advantage over all other approaches in the personalized cancer immunotherapy field, and offers an exclusive opportunity to produce personalized products faster and cheaper.
Predictive Diagnostic Tests
At TREOS we discovered that an individual’s complete HLA genotype is the main determinant of immune responses. This breakthrough led to the development of the PEPI Test (CE Marked) that predicts peptide-specific T cell responses of HLA genotyped individuals. Based on the PEPI Test we have been co-developing with each PolyPEPI™ product a Companion Diagnostic to predict likely responders and improve the diagnostic repertoire of practicing clinicians.
PolyPEPI Preventive Vaccines against Infectious Diseases
Using our proprietary computational vaccine design technology, we have developed a PolyPEPI preventive peptide vaccine against COVID-19 (SARS-CoV-2). The design of PolyPEPI-SCoV-2 exploits our knowledge on genetic heterogeneity of individuals and ethnicities. PolyPEPI-SCoV-2 vaccine can elicit broad and long-lasting immune responses in vaccinated subjects and can therefore protect people against COVID-19, worldwide. PolyPEPI-SCoV-2 product contains 9 different peptide fragments from the four structural protein of the virus. Mutations of the virus will not affect the global coverage of our vaccine; the majority of subjects are expected to have a broad repertoire of virus-specific memory. Preclinical results support the use of our peptide vaccine also in post-exposure prophylaxis, as alternative vaccination strategy (Somogyi et al Front. Immunol 2023).
